VOR Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference

Presentation: Tuesday, November 29, 2022 at 9:30 am ET

Location: Lotte New York Palace Hotel, New York, NY

5th Annual Evercore ISI HealthCONx Virtual Conference

Fireside chat: Thursday, December 1 at 3:05 pm ET

The JMP Securities Hematology and Oncology Virtual Summit

Fireside chat: Tuesday, December 6, 2022 at 1:20 pm ET

A live webcast and archived replay of the presentation and fireside chats will be available on the investors section of our website, linked here:

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contact:

Media & Investors

Sarah Spencer



 



EN
22/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Sh...

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternativ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch